dc.date.accessioned | 2022-03-18T18:09:01Z | |
dc.date.available | 2022-03-18T18:09:01Z | |
dc.date.created | 2022-02-03T19:16:02Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Bernabe, Rosemarie de la Cruz Torres, Cristina E Wangge, Grace Jimenez, Edlyn B Karbwang, Juntra . Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs. Drug Discovery Today. 2021 | |
dc.identifier.uri | http://hdl.handle.net/10852/92606 | |
dc.description.abstract | Clinicians, especially in low- and middle-income countries (LMICs), contend with limited economic and healthcare resources in deciding appropriate and feasible care for their patients. Some of the LMICs affected by COVID-19 implemented convalescent plasma therapy without sufficient regulatory guidance. Based on this experience, there are several requirements going forward, including: the need for an immediately accessible data gathering and processing system; the necessity of establishing regulatory pathways for early access to experimental treatment during emergency situations; and the accompanying reporting and monitoring requirements must be set. The different stakeholders must also be properly incorporated in the system that such a pathway will create, without neglecting to properly inform the public of the patient rights especially during an emergency situation. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs | |
dc.type | Journal article | |
dc.creator.author | Bernabe, Rosemarie de la Cruz | |
dc.creator.author | Torres, Cristina E | |
dc.creator.author | Wangge, Grace | |
dc.creator.author | Jimenez, Edlyn B | |
dc.creator.author | Karbwang, Juntra | |
cristin.unitcode | 185,52,13,0 | |
cristin.unitname | Senter for medisinsk etikk | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1997599 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drug Discovery Today&rft.volume=&rft.spage=&rft.date=2021 | |
dc.identifier.jtitle | Drug Discovery Today | |
dc.identifier.volume | 27 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 686 | |
dc.identifier.endpage | 689 | |
dc.identifier.doi | https://doi.org/10.1016/j.drudis.2021.12.002 | |
dc.identifier.urn | URN:NBN:no-95186 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1359-6446 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/92606/4/1-s2.0-S1359644621005365-main.pdf | |
dc.type.version | PublishedVersion | |